Press Releases Immuneering Corporation

Equities

IMRX

US45254E1073

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
1.38 ^USD	-3.50%		-6.76%	-81.22%

07/05	Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/04	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immuneering to Present at the Jefferies Global Healthcare Conference	30/05	GL
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates	08/05	GL
Immuneering Recognizes Melanoma Awareness Month	07/05	GL
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	09/04	GL
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04/04	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27/03	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27/03	AQ
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	20/03	AQ
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14/03	GL
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14/03	AQ
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12/03	GL
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12/03	AQ
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	11/03	GL
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	06/03	GL
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024	06/03	AQ
Immuneering to Participate in the Cowen 44th Annual Health Care Conference	04/03	GL
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	01/03	GL
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	20/02	GL
Immuneering Announces Participation in February Investor Conferences	01/02	GL
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	12/12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immuneering Corporation

Equities

IMRX

US45254E1073

Press Releases

Filters